Figure 8 | Leukemia

Figure 8

From: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Figure 8

Combination treatment of mice xenografted with JAK3 (M511I) patient 389E. (a) Leukemia burden was followed on basis of human CD45 expression in the peripheral blood. Treatment with vehicle (n=7), ruxolitinib (40 mg/kg/day)(n=7), ABT-199 (20 mg/kg/day; n=7) or ruxolitinib (40 mg/kg/day)+ABT-199 (20 mg/kg/day) (n=8) was begun once CD45%>2% and indicated with an arrow. Treatment continued daily for 14 days. (b) End-stage assessment of human (h)CD45% in the peripheral blood. (c) End-stage assessment of human (h)CD45% in the bone marrow. Significance was calculated using student t-test (***P⩽0.01; **P⩽0.05).

Back to article page